Related Experiment Video
Updated: Jan 30, 2026

Manufacture of Concentrated, Lipid-based Oxygen Microbubble Emulsions by High Shear Homogenization and Serial Concentration
Published on: May 26, 2014
Intravenous Lipid Emulsions in Infants: Is Balanced Better?
Insights
Extremely preterm infants needing parenteral nutrition (PN) risk liver issues like PNAC/IFALD. Novel lipid emulsions with omega-3s may offer protection, but require further study before infant use.
Area of Science:
- Neonatalogy
- Pediatric Gastroenterology
- Nutritional Science
Background:
- Parenteral nutrition (PN) is essential for extremely preterm infants with gastrointestinal issues.
- Prolonged PN can lead to parenteral nutrition-associated cholestasis (PNAC) and intestinal failure-associated liver disease (IFALD).
- Current plant-based lipid emulsions may exacerbate PNAC/IFALD and other comorbidities due to omega-6 fatty acids and phytosterols.
Purpose of the Study:
- To evaluate the potential of alternative intravenous lipid emulsions in preventing PNAC/IFALD in preterm infants.
- To assess the benefits of lipid emulsions with a favorable omega-6:omega-3 ratio, such as SMOFlipid.
- To review existing data supporting the use of SMOFlipid in neonatal intensive care.
Main Methods:
- Review of existing literature on intravenous lipid emulsions in preterm infants.
- Analysis of the composition of plant-based vs. animal-based lipid emulsions.
- Examination of clinical data regarding PNAC/IFALD development and progression.
Main Results:
- Plant-based lipid emulsions contain proinflammatory omega-6 fatty acids and phytosterols.
- Animal-based lipid emulsions, rich in omega-3 fatty acids and antioxidants, may be less inflammatory.
- SMOFlipid, a mixed emulsion, has a favorable omega-6:omega-3 ratio, potentially mitigating liver disease.
Conclusions:
- Alternative lipid emulsions with balanced fatty acid profiles may prevent PNAC/IFALD in preterm infants.
- SMOFlipid shows promise but requires thorough data review before widespread neonatal use.
- Further research is crucial to confirm the safety and efficacy of novel lipid emulsions in vulnerable infant populations.
Abstract:
Parenteral nutrition (PN) is frequently required by extremely preterm infants due to gastrointestinal immaturity and complications of prematurity. Parenteral nutrition-associated cholestasis (PNAC) and intestinal failure-associated liver disease (IFALD) are common complications of prolonged PN. Plant-based intravenous lipid emulsions, containing proinflammatory omega-6 fatty acids and phytosterols, may contribute to these conditions as well as other comorbidities such as bronchopulmonary dysplasia and retinopathy of prematurity. Intravenous lipid emulsions containing animal-based fats, such as fish oil, contain fewer proinflammatory omega-6 fatty acids and more anti-inflammatory omega-3 fatty acids and antioxidants. SMOFlipid, recently Food and Drug Administration (FDA)-approved for adult use, is a blend of plant- and animal-based lipid emulsions with a favorable omega-6:omega-3 ratio that may prevent the development and progression of PNAC/IFALD in infants. Careful review of data supporting this alternative intravenous lipid emulsion is required prior to widespread use in neonatal intensive care.
More Related Videos
Related Concept Videos
Lipid Digestion
Balancing Redox Equations
What are Lipids?
Structure of Lipids
Equilibrium and Balance
Energy Balance

